Patrick Schöffski

机构：Heidelberg University, Rega Institute for Medical Research, University Hospital Heidelberg, VIB-KU Leuven Center for Cancer Biology, Dana-Farber Cancer Institute, KU Leuven · ORCID：0000-0001-5980-030X

发表论文 1167 篇 · 总被引 45081 次 · h-index 93

代表论文

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors (2026 · Nature Cancer · 被引 1)
Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III Trial (2026 · Clinical Cancer Research · 被引 1)
Supplementary Table S7 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment (2026)
Data from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment (2026)
Supp. Fig. 5 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment (2026)
Supp. Fig. 2 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment (2026)